Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,490.80 +103.23 0.67%
S&P 500 1,677.83 +8.67 0.52%
Nasdaq 3,517.99 +15.86 0.45%
Ticker Volume Price Price Delta
STOXX 50 2,830.96 +9.31 0.33%
FTSE 100 6,825.92 +22.05 0.32%
DAX 8,519.45 +47.25 0.56%
Ticker Volume Price Price Delta
Nikkei 15,627.30 +246.24 1.60%
Hang Seng 23,261.10 -105.29 -0.45%
S&P/ASX 200 5,165.37 -14.69 -0.28%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

ZGNX:US

1.5400 USD 0.0200 1.32%

As of 11:29:18 ET on 05/22/2013.

Company Profile for Zogenix Inc (ZGNX)

Zogenix, Inc. is a specialty pharmaceutical company with proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The Company's products candidates include a product that enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.

Contact Information

Zogenix Inc

12671 High Bluff Drive
Suite 200
San Diego, CA 92130
United States
Phone: 1-858-259-1165
Fax: 1-858-259-1166

Key Executives for Zogenix Inc (ZGNX)

Roger L HawleyCEO/Co-FounderStephen J FarrPresident
Cynthia Y RobinsonChief Development OfficerAnn D RhoadsExec VP/CFO/Treasurer/Secy
Richard Scott ShivelyExec VP/Chief Commercial OfcrJohn J TuraninVP/General Mgr:Zogenix Tech
Bret E MegargelVP:Corporate Dev/Co-FounderStephen H JennerVP:Marketing
Edward F Smith IIIVP:Regulatory Affairs & DrugMark R ThompsonVP:Sales & Managed Markets
Jeff D DurflingerVP:Technical Ops & Product Supply

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil